ReviewFrontiers in oncology2026
Molecular pathogenesis and novel therapeutic avenues in alpha-fetoprotein-producing gastric cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-fetoprotein-producing gastric cancer (AFPGC) is a highly malignant subtype of gastric cancer with unique biological characteristics and clinical phenotypes. With the continuous development of molecular biology techniques and diagnostic methods, there has been a deeper understanding of AFPGC in terms of its epidemiological distribution, pathological features, and molecular-level pathogenesis. However, early identification and effective intervention for this type of tumor remain challenging in clinical practice. Current research mainly focuses on discovering potential molecular markers, optimizing diagnostic procedures, and exploring feasible treatment pathways. Despite these efforts, the specific pathogenic mechanism of AFPGC still needs further clarification, and the construction of individualized, multi-modal combined treatment systems also requires further improvement. This article systematically reviews the latest research achievements in the field of AFPGC, aiming to comprehensively sort out the existing knowledge system, provide references for further understanding the complexity of this disease, and promote breakthroughs and innovations in future diagnosis and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.